Table 4.
Comparison of the cytokine levels and laboratory results between survivor and nonsurvivor patients in ADMSCs treatment group.
| Survivors | Nonsurvivors | |||||||
|---|---|---|---|---|---|---|---|---|
| Days | Days | |||||||
| <7 (0 day) | 7–14 (7 day) | 14–28 (14. day) | p | <7 (0 day) | 7–14 (7 day) | 14–28 (14 day) | p | |
| Cytokines | ||||||||
| IL-2 | 49.4 (28.5–304.9) | 116.7 (45.3–258.0) | ND | 0.497 | 34.8 (28.6–83.8) | 50.1 (45.0–50.7) | ND | 0.980 |
| IL-4 | 405.8 (4.3–2597.5) | 305.0 (25.4–2716.7) | ND | 0.530 | 431.0 (395.8–483.3) | 530 (210.0–677.5) | ND | 0.802 |
| IL-10 | 22.3 (0.4–81.7) | 14.0 (9.3–89.9) | ND | 0.891 | 14.7 (11.4–24.5) | 9.4 (7.5–30.1) | ND | 0.777 |
| TNF-α | 137.5 (35.2–557.7) | 100 (8.7–545.4) | ND | 0.985 | 66.6 (47.1–146.2) | 87.5 (47.3–184.8) | ND | 0.215 |
| IF-ɣ | 179.8 (88.2–814.6) | 152.8 (85.5–992.5) | ND | 0.394 | 105.8 (82.2–223.1) | 210.1 (96.7–241.3) | ND | 0.260 |
| Laboratory results | ||||||||
| CRP (mg/ml) | 206 (32–290) | 53 (17–208) | 49 (22–295) | 0.113 | 313 (153–334) | 174 (150–198) | 199 (70–228) | 0.665 |
| PCT (mg/ml) | 3.5 (0.7–100.0) | 1.2 (0.5–56.0) | 0.6 (0.3–7.6) | 0.510 | 6.3 (1.9-100.0) | 2.8 (2.7–2.9) | 2.5 (1.3–4.0) | 0.385 |
| WBC (µ/L) | 18700 (10950–41800) | 11440 (6910–36940) | 7900 (7500–52230) | 0.200 | 13700 (3070–21780) | 7550 (2210–12890) | 11160 (1750–12050) | 0.386 |
| Lactate (mmol/L) | 1.5 (0.8–3.2) | 1.3 (0.8–2.7) | 1.8 (0.8–2.4) | 0.583 | 1.4 (1.0–207) | 2.9 (0.9–4.8) | 1.4 (1.1–1.4) | 0.588 |
| Platelet (103 /μl) | 150000 (26000–479000) | 247000 (35000–925000) | 324000 (40000–791000) | 0.319 | 166000 (121000–266000) | 172000 (118000–194000) | 88000 (80000–124000) | 0.381 |
ND: not done; ADMSCs: allogenic adipose-derived MSCs.